A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy. (PubMed, Future Oncol) - Sep 23, 2026 - P2 | "In 2018, with extensive tumor burden and nearing kidney failure, Laurie enrolled in the ZUMA-5 clinical trial (NCT03105336) and received her seventh and final treatment, a chimeric antigen receptor (CAR) T-cell therapy called axicabtagene ciloleucel (axi-cel)...However, all her side effects from CAR T-cell therapy resolved, and her quality of life returned to her pre-infusion state within 3-4 months. By sharing her experience, Laurie aims to raise awareness for this life-saving and likely curative treatment across multiple audiences that may be impacted by FL, including patients, clinicians, families/caregivers, and advocates."
Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Renal Disease
|